Clinical trials: Propionibacterium
- Condition Propionibacterium
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Acne Vulgaris, Acne
Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne
This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions as anti-acne preparations in human subjects with…
- Conditions
- Acne Vulgaris, Acne, Propionibacterium Acnes
- Trial name
- NCT00211497
- Testing
- MBI 226 Acne Solutions
- Volunteers
- 255 people
- Sponsor
- BioWest Therapeutics Inc
Acne
Evaluation and Detection of Facial Propionibacterium Acnes Bacteria and Phage
This multi-center, outpatient study will extract and evaluate the presence of facial P. acnes bacteria and phage strains using pore strips on up to 400 human subjects.
- Trial name
- NCT03009903
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- MBcure Ltd
Acne Vulgaris
Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne
Comparison of efficacy and safety of Azelaic Acid 15% gel with its vehicle in male and female patients with mild to moderate acne. Qualified subjects will apply the gel to their face twice a day for a period of 12 weeks.
- Trial name
- NCT00031096
- Testing
- Azelaic Acid Gel 15% (Finacea, BAY39-6251), Vehicle gel (SH H 655 PBA)
- Where
- 16 sites in United States
- Volunteers
- 879 people
- Sponsor
- LEO Pharma
Acne Vulgaris, Acne
Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne
This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.
- Conditions
- Acne Vulgaris, Acne, Propionibacterium Acnes
- Trial name
- NCT00211523
- Testing
- MBI 226 Acne Solutions
- Volunteers
- 75 people
- Sponsor
- BioWest Therapeutics Inc